Attana receives an instrument order from global pharma company
Attana has received its first order for the newly launched Attana Cell™ 250 instrument. The order has been placed from an existing pharma customer headquartered in Europe and is the result of several successful contract research projects initiated in the spring of 2018.
In March 2018, Attana announced the order of a smaller contract research project from a global pharma company. Following the success of several smaller research projects the customer has today placed an order for an Attana Cell™ 250 instrument. The order will affect the company’s cashflow and earnings in Q4 2020 and Q1 2021.
“We are always happy to receive new orders, but we are particularly proud that this order comes from an existing contract research customer, validating our core offering. This illustrates what a small contract research project can lead to when we deliver high quality research and the customer appreciates the value of our technology and competence,” comments Teodor Aastrup, CEO Attana.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact email@example.com